NasdaqGS - Nasdaq Real Time Price USD

Genmab A/S (GMAB)

28.75 -0.06 (-0.21%)
As of 9:49 AM EDT. Market Open.
Currency in DKK All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
17,783,000.00
16,474,000.00
14,505,000.00
8,417,000.00
10,111,000.00
Cost of Revenue
411,000.00
226,000.00
--
--
--
Gross Profit
17,372,000.00
16,248,000.00
14,505,000.00
8,417,000.00
--
Operating Expense
11,667,000.00
10,927,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Operating Income
5,705,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Net Non Operating Interest Income Expense
1,014,000.00
912,000.00
303,000.00
184,000.00
174,000.00
Other Income Expense
368,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Pretax Income
7,087,000.00
5,637,000.00
6,945,000.00
3,918,000.00
5,904,000.00
Tax Provision
1,620,000.00
1,285,000.00
1,493,000.00
961,000.00
1,146,000.00
Net Income Common Stockholders
5,467,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Diluted NI Available to Com Stockholders
5,467,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Basic EPS
8.37
6.66
8.34
4.52
7.30
Diluted EPS
8.30
6.60
8.26
4.48
7.22
Basic Average Shares
652,803.80
653,097.44
653,873.01
653,956.37
651,790.06
Diluted Average Shares
658,717.92
659,147.05
660,096.04
660,457.51
658,858.75
Total Operating Income as Reported
5,705,000.00
5,321,000.00
6,267,000.00
2,953,000.00
6,313,000.00
Total Expenses
12,078,000.00
11,153,000.00
8,238,000.00
5,464,000.00
3,798,000.00
Net Income from Continuing & Discontinued Operation
5,467,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Normalized Income
5,183,120.22
4,812,136.95
5,157,615.55
2,367,562.28
5,227,836.38
Interest Income
1,042,000.00
939,000.00
324,000.00
197,000.00
184,000.00
Interest Expense
28,000.00
27,000.00
21,000.00
13,000.00
10,000.00
Net Interest Income
1,014,000.00
912,000.00
303,000.00
184,000.00
174,000.00
EBIT
7,115,000.00
5,664,000.00
6,966,000.00
3,931,000.00
5,914,000.00
EBITDA
7,115,000.00
5,959,000.00
7,328,000.00
4,179,000.00
6,173,000.00
Reconciled Cost of Revenue
411,000.00
226,000.00
--
--
--
Reconciled Depreciation
--
295,000.00
362,000.00
248,000.00
259,000.00
Net Income from Continuing Operation Net Minority Interest
5,467,000.00
4,352,000.00
5,452,000.00
2,957,000.00
4,758,000.00
Total Unusual Items Excluding Goodwill
368,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Total Unusual Items
368,000.00
-596,000.00
375,000.00
781,000.00
-583,000.00
Normalized EBITDA
6,747,000.00
6,555,000.00
6,953,000.00
3,398,000.00
6,756,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
84,120.22
-135,863.05
80,615.55
191,562.28
-113,163.62
12/31/2020 - 6/1/2009

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ASND Ascendis Pharma A/S
134.18
+0.79%
 
INCY Incyte Corporation
53.48
-0.04%
 
BPMC Blueprint Medicines Corporation
107.89
-0.42%
 
LEGN Legend Biotech Corporation
45.33
-0.42%
 
IONS Ionis Pharmaceuticals, Inc.
39.74
+0.68%
 
TECH Bio-Techne Corporation
80.63
+1.36%
 
BBIO BridgeBio Pharma, Inc.
28.94
+0.73%
 
BMRN BioMarin Pharmaceutical Inc.
81.69
-0.04%
 
HALO Halozyme Therapeutics, Inc.
44.08
+0.55%
 
EXEL Exelixis, Inc.
21.83
+0.30%